Synameta Tx

📍 Lausanne, Switzerland👥 4 employees💰 Last funded May 2026
Biotechnology Research
LinkedIn
Synameta Therapeutics is a Swiss biotech company developing next-generation exosome-based vectors for precise, targeted therapeutic delivery. ⚙️ Built on a novel nanomedicine platform, Synameta enables breakthrough medicines to achieve the outcomes they were designed for. We are working on unlocking the full potential of innovative drug candidates by enhancing intracellular delivery, reducing risk in clinical development and amplifying therapeutic impact. 🧬 With applications spanning cancer treatment to gene therapy, the company is working to establish its biovectors as a universal standard for targeted therapeutic delivery, transforming today’s innovations into tomorrow’s cures.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Morocco
1
Frequently asked questions
Who invested in Synameta Tx?
Synameta Tx has 1 investors on record on gritt.io.
When did Synameta Tx last raise funding?
The most recent investment in Synameta Tx recorded on gritt.io was in May 2026.
What industry is Synameta Tx in?
Synameta Tx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Synameta Tx based?
Synameta Tx is headquartered in Lausanne, Switzerland.